» Articles » PMID: 27152962

Animal Models to Achieve an HIV Cure

Overview
Date 2016 May 7
PMID 27152962
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: The introduction of effective antiretroviral therapy (ART) has transformed HIV infection from a deadly to a chronic infection. Despite its successes in reducing mortality, ART fails to cure HIV allowing HIV to persist in vivo. HIV persistence under ART is thought to be mediated by a combination of latent infection of long-lived cells, homeostatic proliferation of latently infected cells, anatomic sanctuaries, and low-level virus replication. To understand the contribution of specific cell types and anatomic sites to virus persistence in vivo animal models are necessary.

Recent Findings: The advancements in ART and our understanding of animal models have facilitated the development of models of HIV persistence in nonhuman primates and mice. Simian immunodeficiency virus (SIV) or simian/HIV infection (SHIV) of rhesus and pigtail macaques followed by effective ART represents the most faithful animal model of HIV persistence. HIV infection of humanized mice also provides a useful model for answering specific questions regarding virus persistence in a uniquely mutable system.

Summary: In this review, we describe the most recent findings using animal models of HIV persistence. We will first describe the important aspects of HIV infection that SIV/SHIV infection of nonhuman primates are able to recapitulate, then we will discuss some recent studies that have used these models to understand viral persistence.

Citing Articles

More than the Infinite Monkey Theorem: NHP Models in the Development of a Pediatric HIV Cure.

Fonseca J, King A, Chahroudi A Curr HIV/AIDS Rep. 2024; 21(1):11-29.

PMID: 38227162 PMC: 10859349. DOI: 10.1007/s11904-023-00686-6.


Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants.

Fray E, Wu F, Simonetti F, Zitzmann C, Sambaturu N, Molina-Paris C Cell Host Microbe. 2023; 31(3):356-372.e5.

PMID: 36809762 PMC: 10583177. DOI: 10.1016/j.chom.2023.01.016.


HIV specific CD8 T-like cells in tonsils express exhaustive signatures in the absence of natural HIV control.

Fardoos R, Nyquist S, Asowata O, Kazer S, Singh A, Ngoepe A Front Immunol. 2022; 13:912038.

PMID: 36330531 PMC: 9623418. DOI: 10.3389/fimmu.2022.912038.


Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo.

Falcinelli S, Peterson J, Turner A, Irlbeck D, Read J, Raines S J Clin Invest. 2022; 132(8).

PMID: 35426377 PMC: 9012286. DOI: 10.1172/JCI157281.


Clearance of HIV-1 or SIV reservoirs by promotion of apoptosis and inhibition of autophagy: Targeting intracellular molecules in cure-directed strategies.

Chen M, Li M, Budai M, Rice A, Kimata J, Mohan M J Leukoc Biol. 2022; 112(5):1245-1259.

PMID: 35362118 PMC: 9522917. DOI: 10.1002/JLB.4MR0222-606.


References
1.
Schafer J, Ries M, Guha N, Connole M, Colantonio A, Wiertz E . Suppression of a Natural Killer Cell Response by Simian Immunodeficiency Virus Peptides. PLoS Pathog. 2015; 11(9):e1005145. PMC: 4557930. DOI: 10.1371/journal.ppat.1005145. View

2.
Spivak A, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus N . A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. 2013; 58(6):883-90. PMC: 3935499. DOI: 10.1093/cid/cit813. View

3.
Garcia J . In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest. 2016; 126(2):424-31. PMC: 4731180. DOI: 10.1172/JCI80562. View

4.
Whitney J, Hill A, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M . Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014; 512(7512):74-7. PMC: 4126858. DOI: 10.1038/nature13594. View

5.
Lifson J, Rossio J, Piatak Jr M, Parks T, Li L, Kiser R . Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol. 2001; 75(21):10187-99. PMC: 114593. DOI: 10.1128/JVI.75.21.10187-10199.2001. View